“…Although this compound exhibits selectivity for the OX1R, particularly at lower doses, there have been some reports that the selectivity and/or stability of SB-334867 may be compromised at higher doses or depending on the preparation (Hollander et al, 2012; McElhinny et al, 2012; Merlo Pich and Melotto, 2014; Winrow and Renger, 2014). The compound used in the current study, GSK1059865, is highly selective for OX1R and exhibits high levels of OX1R occupancy (Bonaventure et al, 2015; Gozzi et al, 2011; Gozzi et al, 2013; Merlo Pich and Melotto, 2014; Piccoli et al, 2012). The compound has no influence on sleep/wake, in contrast with the highly selective OX2R antagonist JNJ10397049 (Gozzi et al, 2011; Piccoli et al, 2012) indicating that behavioral effects of OX1R antagonism are not related to sleep.…”